New-onset type-2 diabetes associated with atypical antipsychotic medications

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 5, 2006, Pages 919-923

  Lambert, Michael T ^a,b   Copeland, Laurel A ^c   Sampson, Nancy ^b   Duffy, Sonia A ^d,e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b North Texas Veterans Health Care Systems   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Atypical antipsychotic agents; Body mass index; Type 2 diabetes mellitus

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 33646899150     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.02.007     Document Type: Article

References (23)

1. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197
2. American Diabetes Association. Consensus development conference on antipsychotic drugs, obesity, and diabetes. Diabetes Care 27 2 (2004) 596-601
3. Beliard S., Valero R., and Vialettes B. Atypical neuroleptics and diabetes. Diabetes Metab 29 3 (2003) 296-299
4. Blow F.C., McCarthy J.F., Valenstein M., Zeber J.E., and Gillon L. Care for veterans with psychosis in the VHA. FY02 4th Annual National Psychosis Registry Report, Ann Arbor, MI VA National Serious Mental Illness Treatment Research and Evaluation Center (SMITREC), health services research and development center of excellence (2003)
5. Caro J.J., Ward A., Levinton C., and Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63 (2002) 1135-1139
6. Citrome L., Blonde L., and Damatarca C. Metabolic issues in patients with severe mental illness. South Med J 98 7 (2005) 714-720
7. Cohen D. Atypical antipsychotics and new-onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry 37 1 (2004) 1-11
8. Department of Veterans Affairs. Antipsychotics and metabolic effects: 2002-2003 update. VHA pharmacy benefits management strategic healthcare group and medical advisory panel (2002) Washington DC
9. Gray D.S., and Fujioka K. Use of relative weight and body mass index for the determination of adiposity. J Clin Epidemiol 44 6 (1991) 545-550
10. Jin H., Meyer J.M., and Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry Mar 1 (2002) 59-64
11. Kornegay C.J., Vasilakis-Scarmozza C., and Jick H. Incidence of diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 63 (2002) 758-762
12. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S.S., Magder L.S., Kreyenbuhl D.A., et al. Assessment of independent effect of olanzapine on risk of diabetes among patients with schizophrenia: population-based nested case-control study. BMJ (2002) 243-247
13. Kropp S., Grohmann R., Hauser U., Ruther E., and Degner D. Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project. Pharmacopsychiatry 37 suppl 1 (2004) S79-S83
14. Leslie D.L., and Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161 9 (2004) 1709-1711
15. Marder S.R., Essock S.M., Miller A.L., Buchanan R.W., Davis J.M., Kane J.M., et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28 1 (2002) 5-16
16. McTigue K. Screening and interventions for overweight and obesity in adults: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med 139 11 (2003) 933-949
17. Melkerson K., and Dahl M.L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64 (2004) 701-723
18. Nasrallah H.A. Pharmacoeconomic implications of adverse effects of antipsychotic therapy. Am J Health Syst Pharm 15 22 Suppl 8 (2002) S16-S21
19. Ryan M.C., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 160 2 (2003) 284-289
20. Thompson Healthcare Online, 2004. MicroMedex Online. 4;123 (March).
21. U.S. Department of Health and Human Services. National Diabetes Fact Sheet: general information and national estimates on diabetes in the United States, 2002 (2002), U.S. Department of Health and Human Services, Center for Disease Control, Atlanta, U.S.A.
22. Wirshing D.A., Boyd J.A., and Meng L.R. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63 (2002) 856-865
23. Wolf A.M., and Colditz G.A. Current estimates of the economic cost of obesity in the United States. Obes Res 6 2 (1998) 97-106